VISTAGEN THERAPEUTICS, INC.

VTGN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Operating Activities
Net Income $-14.3M $-10.3M $-47.2M $-13.9M $-3.0M $-12.9M $-12.2M $-9.5M
Depreciation & Amortization $80.7K $54.9K $53.5K $59.1K $54.6K $33.8K $45.6K $45.3K
Depreciation
Amortization
Stock-Based Compensation $2.5M $1.1M $1.2M $1.6M $1.6M
Net Cash from Operating Activities $-9.1M $-7.3M $-4.8M $-2.8M $-2.1M $-3.5M $-3.6M $-841.3K
Investing Activities
Capital Expenditures $1.6K $239.1K $26.3K
Business Acquisitions
Net Cash from Investing Activities $-1.6K $-239.1K $-26.3K $9.6K $-135.4K $-32.4K $-57.8K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $16.5M $2.8M $1.5M $4.2M $3.5M $837.4K
Net Change in Cash $7.5M $2.5M $358.5K $70.0K $-638.1K $557.1K $-58.3K $-61.7K
Free Cash Flow $-9.1M $-7.5M $-4.8M
← Newer Page 2 of 4 Older →